Publicaciones en las que colabora con Bruno Carlos Sangro Gómez-Acebo (25)

2024

  1. Application of Graph Models to the Identification of Transcriptomic Oncometabolic Pathways in Human Hepatocellular Carcinoma

    Biomolecules, Vol. 14, Núm. 6

  2. Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis

    JHEP Reports, Vol. 6, Núm. 8

  3. Comprehensive in silico CpG methylation analysis in hepatocellular carcinoma identifies tissue- and tumor-type specific marks disconnected from gene expression

    Journal of Physiology and Biochemistry

  4. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

  5. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5

2023

  1. Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 901-924

  2. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  3. Mapping early serum proteome signatures of liver regeneration in living donor liver transplant cases

    BioFactors, Vol. 49, Núm. 4, pp. 912-927

2022

  1. DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

    Cancers, Vol. 14, Núm. 9

  2. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  3. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures

    Gut, Vol. 71, Núm. 6, pp. 1141-1151

2021

  1. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

    Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30

  2. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  3. Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: Dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis

    Gut, Vol. 70, Núm. 2, pp. 388-400

  4. Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage

    Hepatology, Vol. 74, Núm. 5, pp. 2791-2807

  5. The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation

    Nucleic Acids Research, Vol. 49, Núm. 15, pp. 8592-8609

2020

  1. Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis

    Cancers, Vol. 12, Núm. 12, pp. 1-27

  2. Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach

    Cancers, Vol. 12, Núm. 6, pp. 1-30

2019

  1. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis

    Hepatology, Vol. 70, Núm. 2, pp. 547-562

  2. Splicing events in the control of genome integrity: Role of SLU7 and truncated SRSF3 proteins

    Nucleic Acids Research, Vol. 47, Núm. 7, pp. 3450-3466